WIN 55,212-2

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
WIN 55,212-2
File:WIN55212-2.svg
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H26N2O3
Molar mass522.61 g/mol
3D model (JSmol)

WIN 55,212-2 is a drug described as an aminoalkylindole derivative, that produces effects similar to those of Cannabinoid derivatives such as THC but has an entirely different chemical structure.[1][2][3]

WIN 55,212-2 is a potent cannabinoid receptor agonist [4] which has been found to be a potent analgesic[5] in a rat model of neuropathic pain[6]. It activates p42 and p44 MAP kinase via receptor-mediated signaling[7].

WIN55,212-2, along side HU-210 and JWH-133, are implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This antiinflamatory action is induced through the agonization of cannabinoid receptors which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.

WIN55212-2 is a weaker partial agonist than THC, but with higher affinity to the CB1 receptor. [8] This means that the threshold dose for onset of effects is smaller than that of THC, but the maximum effects attainable are not as strong as those of THC, meaning that WIN55212-2 could potentially be used as a legal cannabis substitute drug, for instance as an alternative to medical marijuana. WIN55212-2 produces cannabis-like effects in humans within the oral dosage range of 1 to 3 miligrams however the effects are described as milder and shorter lasting when compared to THC[citation needed].

External links

  • Biomol Win 55,212-2 Data Sheet
  • The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. 2006 Jul 18; Template:PubMed
  • JNeurosci.orgPrevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
  • New Scientist: Hope for cannabis-based drug for Alzheimer's

References

  1. ↑ Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole Analogs: Cannabimimetic Activity of a Class of Compounds Structurally Distinct from Δ9-Tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics. 1992; 263(3):1118-1126.
  2. ↑ Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T. The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vitro and In Vivo Study. Cerebral Cortex. 2001; (11):728-733.
  3. ↑ Zhang Q, Ma P, Iszard M, Cole RB, Wang W, Wang G. In Vitro Metabolism of R(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a Cannabinoid Receptor Agonist. Drug Metabolism and Disposition. 2002; 30(10):1077-1086.
  4. ↑ C.C. Felder et al. Mol. Pharmacol. 1995 48 443
  5. ↑ I.D. Meng et al. Nature 1998 395 381
  6. ↑ U. Herzberg et al. Neurosci. Lett. 1997 221 157
  7. ↑ M. Bouaboula et al. Biochem. J. 1995 312 637
  8. ↑ Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 1993 Mar;264(3):1352-63.

Template:Pharma-stub Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=WIN_55,212-2&oldid=728143"